Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) announced that Chairman and CEO Dr. Amit Kumar is featured on the Water Tower Research Healthcare Happenings podcast on March 12, 2026. Dr. Kumar discusses positive clinical trial data for the breast cancer vaccine and ovarian cancer CAR-T therapy, plus future plans and the company's financial condition. The podcast is available at the Water Tower Research media page.
Positive
- None.
Negative
- None.
News Market Reaction – ANIX
On the day this news was published, ANIX declined 2.72%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
Sector peers show mixed moves: SRZN, STTK and TCRX are down, PYXS is flat, while ADAG is up 21.16%. Momentum scanner only flags MGNX down 6.89%, suggesting ANIX’s action is more stock-specific than part of a broad sector swing.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | Patent allowance | Positive | +4.6% | Korean patent allowance expanding IP for breast cancer vaccine technology. |
| Mar 02 | Annual meeting update | Positive | -0.7% | Annual meeting with clinical and regulatory updates including dose escalation approval. |
| Feb 23 | Conference keynote | Positive | +1.7% | Keynote on FSHR‑mediated CAR‑T Phase 1 trial at research retreat. |
| Feb 09 | Clinical data update | Positive | +0.7% | Encouraging survival and major dose escalation in ovarian cancer CAR-T trial. |
| Feb 02 | Drug naming milestone | Positive | -3.3% | USAN approval of non‑proprietary name for FSHR‑targeted CAR‑T therapy. |
Recent news has generally been positive, but price reactions have been mixed, with both rallies and selloffs on favorable clinical and regulatory updates.
This announcement follows a series of oncology-focused milestones. On Mar 9, Anixa received a Korean patent allowance for its breast cancer vaccine after Phase 1 data showed immune responses in 74% of participants. Earlier updates highlighted substantial dose-escalation approval and encouraging survival in the ovarian cancer CAR-T Phase 1 trial, as well as naming approval for liraltagene autoleucel. Market reactions to these positive items ranged from a 4.56% gain to a 3.29% decline, underscoring inconsistent trading responses to good news.
Regulatory & Risk Context
The company has an active Form S-3 shelf registration filed on 2025-09-10. It covers multiple security types and has not yet been used (usage count 0). The filing details offering expenses and book value metrics but provides flexibility for future capital raises, subject to effectiveness.
Market Pulse Summary
This announcement highlights increased investor outreach as Anixa’s CEO discusses positive data from its breast cancer vaccine and ovarian cancer CAR-T programs on a healthcare podcast. It follows recent Phase 1 successes and international patent progress. With shares trading below the 200-day MA and prior news drawing mixed market responses, investors may focus on clarity around trial timelines, upcoming milestones, liquidity disclosures in recent SEC filings, and how management frames future development plans.
Key Terms
clinical trials medical
CAR-T therapy medical
AI-generated analysis. Not financial advice.
During the podcast, Dr. Kumar discusses the positive data observed in theclinical trials of its breast cancer vaccine and ovarian cancer CAR-T therapy. Dr. Kumar also discusses future plans and the financial condition of the Company.
To listen to the podcast, please visit: https://www.watertowerresearch.com/media-detail/3233/Media.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-featured-on-water-tower-research-healthcare-happenings-podcast-302712463.html
SOURCE Anixa Biosciences, Inc.
FAQ
What did Anixa (ANIX) discuss on the March 12, 2026 Water Tower Research podcast?
Where can investors listen to the Anixa (ANIX) Water Tower Research Healthcare Happenings podcast?
Does the podcast provide specific clinical trial results for Anixa (ANIX)?
Will the Anixa (ANIX) podcast remarks affect the company's near-term plans?
Who represented Anixa (ANIX) on the Water Tower Research Healthcare Happenings podcast?
